CON Lifts Guidance After 17% Revenue Growth and Expansion in Occupational Health Centers
Double-Digit Revenue Growth and Expanded Network Mark a Strong Quarter
Concentra (NYSE:CON) posted robust third quarter results, spotlighted by a 17% year-over-year increase in revenue to $572.8 million and a network expansion to 628 occupational health centers and 413 onsite clinics nationwide. The nation’s largest provider of occupational health services also raised its full-year guidance, reflecting continued momentum from higher visit volumes and enhanced operational performance.
Patient Volume and Margin Metrics Continue Upward Trajectory
The quarter saw total patient visits climb to 3.56 million—a 9.2% increase from the previous year’s third quarter—with visits per day averaging 55,589. Revenue per visit increased 4.2% to $147.31, supporting net income of $49.8 million and Adjusted EBITDA of $118.92 million (up 17.1% year-over-year).
| Key Metric | Q3 2025 | Q3 2024 | % Change |
|---|---|---|---|
| Revenue | $572.8M | $489.6M | +17.0% |
| Adjusted EBITDA | $118.9M | $101.6M | +17.1% |
| Net Income | $49.8M | $45.8M | +8.9% |
| Adjusted EPS | $0.39 | $0.37 | +5.4% |
| Total Patient Visits | 3,557,697 | 3,258,605 | +9.2% |
| Revenue per Visit | $147.31 | $141.42 | +4.2% |
| Occupational Health Centers | 628 | 549 | +14.4% |
| Onsite Health Clinics | 413 | 156 | +164.7% |
Financial Position Remains Strong as Company Returns Capital to Shareholders
CON ended the quarter with a cash balance of $49.9 million and reduced net leverage to 3.6x, in line with management’s target of 3.5x or below by year-end. The Board approved a quarterly dividend of $0.0625 per share and authorized a $100 million share repurchase program—actions signaling confidence in the company’s cash flow and future prospects.
Raised Full-Year Outlook on Continued Execution
Management now projects 2025 revenue between $2.145 billion and $2.16 billion, with Adjusted EBITDA of $425–$430 million. The updated guidance comes as Concentra sees continued strength from higher patient volumes and efficient operational discipline, even while balancing investment in technology and a complex corporate separation from Select Medical.
| 2025 Guidance | Prior Range | New Range |
|---|---|---|
| Revenue | N/A | $2.145B–$2.16B |
| Adjusted EBITDA | N/A | $425M–$430M |
| Net Leverage Ratio | 3.5x or below | 3.5x or below |
Strategic Investments Drive Network and Earnings Growth
Concentra’s investment in technology and continued network expansion has been central to its performance, with an 8.9% increase in net income and stable Adjusted EBITDA margin near 21%. General and administrative expenses did rise 42.6% from the prior year’s quarter, but this included integration, technology, and transition costs related to strategic growth and separation from Select Medical.
Takeaway: Steady Execution with Capital Returns
Concentra’s Q3 results underscore the benefits of operational focus, network scale, and patient volume growth. The expanded dividend and new buyback program provide investors with tangible capital returns while the raised full-year outlook reflects management’s optimism. Investors may want to follow Concentra’s next steps, especially its upcoming November 7 conference call for additional color on integration, network development, and market outlook for occupational health services.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI